Avinger, Inc. announced that it has entered into a Securities Purchase Agreement with new investor, Zylox-Tonbridge Medical Technology Co., Ltd., pursuant to which the Purchaser agreed to purchase the shares of the Company?s common stock, par value $0.001 per share and shares of two new series of the Company?s preferred stock for the aggregate gross proceeds of $15,000,000 on March 4, 2024. The purchaser agreed to purchase in two tranches. Each share of Series F Preferred Stock has a stated value of $1,000 and is initially convertible into approximately 273 shares of Common Stock at a conversion price equal to the Purchase Price, subject to the terms of the Certificate of Designation of Preferences, Rights, and Limitations of the Series F Preferred Stock.